In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 15, No. 693 ( 2023-04-26)
Abstract:
Respiratory syncytial virus (RSV) remains an urgent health issue for infants and the elderly. Recent advances in RSV vaccine development have provided critical insights into the design of vaccine immunogens that can induce protective immunity. Che et al . now describe the optimization of RSV prefusion F constructs with an ability to induce higher neutralizing antibodies than the prototype vaccine antigen DS-Cav1 in preclinical studies. They identified stabilizing mutations that were used to modify the backbones of dominant circulating RSV A and B subgroups to create a bivalent vaccine that was effective in protecting cotton rats against an RSV challenge. These results highlight the importance of vaccine immunogen optimization for enhancing protective immunity against RSV and have been used to advance this vaccine to phase 3 trials. —CF
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.ade6422
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023
Permalink